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Hg (20.140 mm Hg). Immediate post-stent gradient was 15 mm Hg (0-60 mm Hg, 
p<.001). Median follow-up was 39 months (12-78 months). Seven patients had repeat 
study. Additional stents were implanted in 2 patients and 5 underwent stent re-dilation. At 
re-study, median gradient was 37 mm Hg (10-55 mm Hg), with post-dilation gradient of 
12 mm Hg (0.40 mm Hg). Two procedure-related complications were noted. One stent 
was deployed in the femoral artery after dislodging during implantation. At restudy, one 
patient was found to have developed multiple aneurysms adjacent to stents implanted in 
the thoracic aorta and brachiocephalic vessels. Conclusions: Stent implantation is 
effective in providing gradient relief in SAA. Early procedure related complications are 
uncommon and gradient relief persists or is amenable to re-dilation. Uncomplicated stsnt 
implantation does not preclude aneurysm formation, however. This complication may be 
related to histopathologic and vessel wall-specific issues, making prediction of which 
patients are at risk difficult. 
1190-98 Tranacetheter Aortic Valvuloplasty Assisted by Right 
Ventricular Pacing 
Frank F. Ino. Nicole K. Boramanand, James Mathewson, Kathleen Maginot, James C. 
Perry, Children's Hospital of San Diego, San Diego, California, UCSD, School of 
Medicine, San Diego, California. 
Background: Transcathetsr aortic valvuloplasty (TAV) is a well-established treatment 
modality for congenital aortic valve stenosis. However during dilation, inadvertent balloon 
movement (due to the contractile force of the left ventricle) can increase risk of unneces- 
sary trauma to the aortic valve apparatus resulting in aortic insufficiency (AI). A new tech- 
nique was developed to stabilize balloon position dudng dilation. Methods: Standard 
transfemorel retrograde techniques were used for TAV. A pacing catheter was inserted 
into the right ventricle (RV) apex and just pdor to balloon inflation, the heart was paced at 
a faster rate in order to decrease the stroke volume and left ventricle (LV) systolic pres- 
sure. The lower LV stroke volume and systolic pressure result in a more stable balloon 
position. Balloon inflation was carried out in the usual manner and following balloon 
deflation, RV pacing was discontinued. Echocardiographic and cath lab data were 
reviewed in all patients who underwent TAV assisted by RV pacing between 9/99 and 8/ 
01. Results: Thirteen patients underwent TAV assisted by RV pacing (31 inflations). 
Mean age and weight were 9.9 years and 31.7 kg respectively. The aortic valve gradient 
decreased from 67.8 ± 18.8 to 19.4 ± 9.1 mmHg (75%). The average balloon to annulus 
ratio was 0.92 ± 0.08. RV pacing increased the hearf rate by an average of 80 ± 29% and 
decreased LV systolic pressure by 36 ± 12%. Balloon position remained stable dudng 
inflation in all except for one when there was loss of capture resulting in a premature ven- 
tricular contraction (PVC). Review of the fluoroscopic and hemodynamic recording of that 
inflation indicated the balloon "milked" forward during the PVC. Normal sinus rhythm 
returned in all cases immediately after RV pacing was discontinued. No change in AI or 
trace AI was seen in 10 pts. The development of mild AI was seen in 3 (1+ in 1 and 2+ in 
2 pts). Conclusion: RV pacing dudng TAV is safe and stabilizes balloon position during 
aortic valve dilation. Larger series and longer foUow-up are warranted to confirm that sta- 
ble balloon position during TAV decreases the incidence of aortic insufficiency. 
1190-99 Int racerd iac  Echocardiography During In tarvent iona l  
Catheterization for Congenital Heart Defects 
~lQhn F. Rhodes. Jr.. Tamar J. Preminger, Cesar I. Mesia, Geoffrey K. Lane, Lourdes R. 
Prieto, Larry A. Latson, The Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Echocardiographic guidance is often used during transcatheter interven- 
tions for patients with congenital heart defects. Few data exist regarding intracardiac 
echocardiographic (ICE) guidance during transcatheter interventions. We report data 
from a single center regarding the efficacy and performance of ICE for this patient popu- 
lation. Methods: The 10Fr AcuNav TM ICE catheter provides a 2-dimensional image and 
Doppler color mapping using the Sequoia ultrasound system, Between 5/01 and 9/01, 
data were collected prospectively from patients undergoing interventional procedures 
using ICE and conscious sedation. The ICE catheter was positioned through an 11Fr 
sheath in the right atrium. Results: Seventeen patients, median age 48 years (range 12 
to 77), underwent a transcatheter intervention for a congenital heart defect with ICE guid- 
ance. Twelve patients underwent patent foramen ovals (PFO) closure, two patients atdal 
septal defect (ASD) closure and three patients balloon aortic valvuloplasty (BAV). ICE 
allowed the patients to avoid general anesthesia and transesophageal echocardiography 
(TEE). iCE provided accurate monitoring for placement of devices during PFO/ASD clo- 
sure and degree of valvar regurgitation during BAV. There were no procedure related 
adverse events. The median fluoroscopy time for PFO/ASD closure was 17 minutes 
(range 11 to 36) and for BAV procedures was 30 minutes (range 21 to 88). Overall bill- 
able charges were less for the ICE group when compared to the potential charges of the 
procedure including general anesthesia and TEE. All patients were discharged <24 
hours following the catheterization. With a median follow-up of 2.4 months (range 0,7 to 
3.8) there have been no adverse events. Conclusion: ICE is a safe and effective 
method for guidance during interventional procedures for patients with congenital heart 
defects. The avoidance of general anesthesia and TEE may be significant o the patients 
overall procedural experience and be more cost effective. These data support continued 
utilization of this type of technology. 
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1190-100 Intermediate Follow-Up for Atrial Septal Defect Closure 
With the HELEX TM Septal Occluder Device: The FDA 
Phase I Feasibility Trial  
John F. Rhodes. Jr., Geoffrey K. Lane, David Nykanen, Penny A. Radvansky, Evan M. 
Zahn, Larry A. Latson, The Cleveland Clinic Foundation, Cleveland, Ohio, Miami 
Children's Hospital, Miami, Flodda. 
Background: The Helex TM device has recently been used for transcatheter secundum 
atrial septal defect (ASD) closure. We report the intermediate follow-up data regarding 
device safety and performance. Methods: Between 4/00-12/00, pts with an ASD in two 
centers were enrolled in a prospective, non-randomized FDA phase-I feasibility trial. 
Catheterizations were performed using general anesthesia with transesophageal 
echocardiography guidance. Procedural success was defined as accurate placement of 
a device. Evaluations were scheduled for 1-day, 1 -month, 6-months and 1-year following 
deployment. Results: Fifty-five pts with an ASD, median age 10yrs (range 0.4 to 55), 
proceeded to the catheterization laboratory. Static balloon-stretched ASD diameter was 
7.1-->26mm (17+4.4). Device/balloon waist ratio was 1.3~4.2 (1.8¢0.5). The procedure 
was successful in 50 pts. There were 7 procedure-related adverse events with device 
embolization (uneventful retrieval) in 2-pts, transient arrhythmia in 3-pts and transient ST 
depression in 2-pts. Median fluoroscopy time was 23 minutes. No adverse event pro- 
longed the hospitalization. No pt had a clinically significant residual leak around the 
device. The incidence of triviaVsmall leaks has decreased from 27/50 (54%) at 1-day to 
22/47 (47%) at 1-month and 9/30 (30%) at 6-months. At this time, 1-year follow-up is 
available in 15 pts with 2 (13%) having a trivial/small eak around the device and one 
having a small residual shunt through a second ASD. The only adverse events reported 
during follow-up have been 1-pt with nosebleed and 1-pt with rectal bleeding. Both 
resolved with a decrease in the standard aspirin anticoagulation regimen. Although no pt 
has had new onset documented arrhythmia, 2-pts have had complaints of palpitations 
and 2-pts have had return of atrial arrhythmia after implantation. With a median follow-up 
of 210 days (range 27 to 358) there have been no device fractures. Conclusion: These 
intermediate data indicate that the Hetex TM device is safe and effective for secundum- 
ASD closure. At latest follow-up no pt has a clinically significant residual leak and the 
incidence of clinically insignificant leak appears to decrease. 
1190-101 Amplatzer Fenestration Device: Application in Humane 
to Mainta in  Patency  o f  Fontan Fenestration and Shunt 
Through the Atrial Septum 
Zahid Amin, David A. Danford, Carlos A. Pedra, Univ of Nebreska/Creighton Univ., 
Children's Hospital, Omaha, Nebraska, Instituto Dante Pazzanese de Cardiologia, Sad 
Paulo, Brazil. 
Background: Patients who develop systemic venous failure and protein-losing enteropa- 
thy after lateral tunnel or extracardiac Fontan, may benefit from fenestration created 
between the systemic and pulmonary venous channels. Some fenestrations, whether 
created surgically or in the cathetedzstion laboratory, tend to close spontaneously. In 
addition, patients with pulmonary hypertension or ventdcular dysfunction and atrial septal 
defect may benefit from a small communication at the atrial level, if the defect is closed. 
The objective of this study was to assess the feasiblity of a new Amplatzer device, to 
maintain patency of Fontan Fenestration and atrial level communication, after closure of 
the atrial septal defect. Methods: Amplatzar Septal Occlude~ was modified to create a 
4-ram fenestration through the discs and the waist of the device. The basic design, load- 
ing, delivery, deployment and release mechanism were similar Amptatzer Septal 
Occloder. Three patients with protein-losing enteropathy after Fontan operation, under- 
went placement of the device. A fenestration was created in the Goretsx patch of the lat- 
eral tunnel with the help of transsepta( needle. The fenestration was dilated with 8-mm 
balloon, and the 4-mm Fenestration device (8-mm disc) was deployed under transesoph- 
ageal echocardiographic guidance. The fourth patient, who had ventricular dysfunction, 
had the device placed in the atdal septal defect. Relulte: The procedure was successful 
in all patients. There was immediate drop in systemic artedal saturations and systemic 
venous pressures after placement of the device. All patient showed dramatic hemody- 
namic improvement. Follow-up was available from 3 to 12 months. Echocardiographic 
evaluation at the last follow-up revealed low velocity flow through the fenestrations. Con- 
clusions: This limited expedenca suggest that the Amplatzer Fenestration device can be 
a valuable tool in keeping Fontan Fenestrations patent. It can also maintain a communi- 
cation at the atrial level in patients with pulmonary hypertension or ventricular dysfunc- 
tion after atria~ septal defect closure. 
1190-102 Quant i ta t ive  Angiographic Assessment of Pulmonary 
Blood Flow in Children With Congenital Heart Defects 
Daniel H. Gruenstein. Robert H. Beekman, III, Robert L. Spicer, Children's Hospital 
Medical Center, Cincinnati, Ohio. 
Background: This study was performed to validate a new method of quantifying relative 
pulmonary blood flow by angiography. 
Methods: Pulmonary angiograms and radionuclide lung perfusion scans (LPS) of 12 
children with various congenital heart malformations were compared. Relative blood flow 
to the left and right lung was measured by pulmonary angiographic densitometry lAD) 
using a new image analysis protocol. Perfused regions of the left and right lung were 
defined and the cross-sectional area and mean contrast density in each region of interest 
was quantitated. The ratio of right pulmonary artery flow to total lung flow was deter- 
mined by AD, expressed as a percent (QPAo), and was compared to the ratio of right pul- 
monary flow as determined by LPS (QPLPS)" Observers blinded to the LPS data 
performed the AD measurements, and intraobserver and interobserver variability was 
determined, 
Results: The QPAo ranged from 15-100% (mean +/- SD = 52 +/- 26), and the QPLPS 
ranged from 17-97% (57+/- 26). There was a significant linear relation between QPAD 
